Coronary artery disease

17 trials 10 recruiting MedDRA PT
17 Registered trials
10 Recruiting
16 Unique sponsors
21 Unique IMPs
9 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
B Haematology (ATC B) 4
C Cardiology (ATC C) 5
M Musculoskeletal (ATC M) 1
A Gastroenterology (ATC A) 1
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 14 substances
Antiplatelet / NSAID 2 substances
Statin 1 substance
Supportive / diluent 1 substance
SGLT2 inhibitor 1 substance
GLP-1 receptor agonist 1 substance
Analgesic / antipyretic 1 substance
Phase III: 7 Phase II/III: 1 Phase II: 4 Phase IV: 3 Phase I: 1 Phase I (Other): 1

Filter these 17 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 17 trials

Phase III

7 trials
  • Ivascular S.L. Commercial
    IMP not specified
    2023-507015-35-00 3 countries 2023 n=2,312
    Ended
  • Novartis Pharma AG Commercial
    IMP not specified
    2024-511126-31-00 6 countries 2022 n=173
    Ended
  • Synektik S.A. Commercial
    ADENOSINE; REGADENOSON; SYN2
    2023-506971-89-00 5 countries 2024 n=220
    Recruiting
  • Win Medica Pharmaceutical S.A. Commercial
    AMIODARONE HYDROCHLORIDE; FLECAINIDE ACETATE
    2024-519233-33-00 1 country 2023 n=200
    Ended
  • Dolnoslaskie Centrum Chorob Serca Im. Prof. Zbigniewa Religi Medinet Sp. z o.o. Academic
    IMP not specified
    2025-521892-30-00 1 country 2025 n=1,703
    Recruiting
  • Universitair Ziekenhuis Gent Academic
    COLCHICINE
    2023-505028-74-00 1 country 2024 n=2,770
    Recruiting
  • Weill Medical College Of Cornell University Academic
    ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PH. EUR.; TICAGRELOR
    2023-506613-22-00 3 countries 2024 n=300
    Recruiting

Phase II/III

1 trial
  • Semmelweis University Academic
    ROSUVASTATIN
    2025-522868-32-00 1 country n=140
    Pending

Phase II

4 trials
  • Ribocure Pharmaceuticals AB Commercial
    ACETYLSALICYLIC ACID; RBD4059
    2023-510370-14-00 1 country 2024 n=30
    Ended
  • Synektik S.A. Commercial
    ADENOSINE; REGADENOSON; SYN2
    2023-507520-23-00 1 country 2024 n=30
    Recruiting
  • Xylocor Therapeutics Inc. Commercial
    ENCOBERMINOGENE REZMADENOVEC
    2025-521325-33-00 4 countries 2026 n=90
    Ended
  • Hospital San Pedro Academic
    LIDOCAINE HYDROCHLORIDE; SODIUM CHLORIDE
    2025-523534-11-00 1 country 2025 n=90
    Recruiting

Phase IV

3 trials
  • Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy Academic
    DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SEMAGLUTIDE
    2023-508525-27-00 1 country 2025 n=300
    Recruiting
  • Pohjois-Savon hyvinvointialue Academic
    OXYCODONE HYDROCHLORIDE; PARACETAMOL
    2024-515530-33-00 1 country 2025 n=100
    Recruiting
  • Wellbeing Services County Of North Karelia Siun Sote Academic
    ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL; TICAGRELOR
    2023-504340-34-01 3 countries 2024 n=734
    Recruiting

Phase I

1 trial
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2025-524693-42-00 1 country 2026 n=196
    Recruiting

Phase I (Other)

1 trial
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Synektik S.A. Commercial 2 Phase II, Phase III 2
F. Hoffmann-La Roche AG Commercial 1 Phase I 1
Bayer AG Commercial 1 Phase I (Other) 0
Ribocure Pharmaceuticals AB Commercial 1 Phase II 0
Xylocor Therapeutics Inc. Commercial 1 Phase II 0
Ivascular S.L. Commercial 1 Phase III 0
Novartis Pharma AG Commercial 1 Phase III 0
Win Medica Pharmaceutical S.A. Commercial 1 Phase III 0
Semmelweis University Academic 1 Phase II/III 0
Hospital San Pedro Academic 1 Phase II 1
Dolnoslaskie Centrum Chorob Serca Im. Prof. Zbigniewa Religi Medinet Sp. z o.o. Academic 1 Phase III 1
Universitair Ziekenhuis Gent Academic 1 Phase III 1
Weill Medical College Of Cornell University Academic 1 Phase III 1
Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy Academic 1 Phase IV 1
Pohjois-Savon hyvinvointialue Academic 1 Phase IV 1
Wellbeing Services County Of North Karelia Siun Sote Academic 1 Phase IV 1
New trials by year
2022
1
2023
2
2024
6
2025
4
2026
2
← All indication landscapes